Deutsche Bank disclosed a new stake in Amylyx Pharmaceuticals, having purchased 557,937 shares in the second quarter, a position valued at over $10 million. This move is part of a broader trend of increased institutional investment, with other firms like Millennium Management and Goldman Sachs also recently increasing their holdings in the company.
This influx of institutional capital follows the highly positive topline results from Amylyx's Phase 3 LUCIDITY trial for its drug avexitide, which were announced on August 18, 2026. The successful trial data prompted the company to launch a common stock offering that was upsized to $500 million due to strong investor demand.
The market reaction has been strongly positive, with analysts raising their price targets. Robert W. Baird increased its target to $52, and HC Wainwright maintained a Buy rating with a $55 target, signaling confidence in the company's future commercial prospects. Trading volume for the stock has also been substantially above average.